Answer
Safinamide inhibits OCT1 in vitro at clinically relevant portal vein concentrations, potentially increasing exposure to metformin, an OCT1 substrate with a similar time to peak concentration of about two hours.
Sources for this answer
- Xadago 50mg film-coated tabletsZambon UK Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 7Document updated
Sources checked